Navigation Links
Positive Results for Second-Generation Taxus Liberte Coronary Stent,System Highlighted in Journal of American College of Cardiology

Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com .

This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission.

    CONTACT:  Paul Donovan

              508-650-8541 (office)

              508-667-5165 (mobile)

              Media Relations

              Boston Scientific Corporation


              Dan Brennan

              508-650-8538 (office)

              617-459-2703 (mobile)

              Investor Relations

              Boston Scientific Corporation

(1) The TAXUS Liberte stent is currently pending approval by the U.S. Food and Drug Administration and is not available for sale in the United States.

(2) Defined as B2 or C lesions (ACC/AHA lesion type)

Boston Scientific Corporation

CONTACT: Paul Donovan, Media Relations, +1-508-650-8541, Mobile,+1-508-667-5165, or Dan Brennan, Investor Relations, +1-508-650-8538,Mobile, +1-617-459-2703, both of Boston Scientific Corporation

Web site: http://www.bostonscientific.com/

Ticker Symbol: (NYSE:BSX)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Busi
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:8/21/2008)...d EMERYVILLE, Calif., Aug. 21 /PRNewswire-FirstCal...nyx Pharmaceuticals, Inc.,(Nasdaq: ONXX ) today a...ts,in the STORM Sorafenib as Adjuvant Treatment in...rcinoma trial. The randomized, double-blind,place...R) (sorafenib),tablets as adjuvant treatment, whic...
(Date:8/20/2008)... 20 /- Enobia Pharma, an emerging bio...ics for serious bone,disorders, today announced th...ypophosphatasia has been dosed. Enobia is investig...40 for the treatment of this rare and,often crippl...proved,treatment., Under two separate protocols, ...
(Date:8/19/2008)...lia, Aug. 20 /Xinhua--,Phar...SL) today announced,that the Phase 3 clinical tria... subjects with bronchiectasis has concluded with n...llowing 12 months of treatment., A total of 123 s...wice,per day and 99 subjects completed the full 12...
(Date:8/19/2008)...nd tissue samples to be used to identify molecular...ss., Aug. 19 /PRNewswire-USNewswire/ -- ALS Therap...the acceleration of an ALS,biomarker effort using ...k,of clinical partnerships. These ongoing projects...ndentify the altered expression of genes,and prote...
Breaking Medicine Technology:Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer 2Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer 3Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer 4Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer 5Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia 2Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia 312 Month Phase 3 Trial Finds Bronchitol Safe in Bronchiectasis 212 Month Phase 3 Trial Finds Bronchitol Safe in Bronchiectasis 3ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrig's Disease 2ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrig's Disease 3HIV Drugs Linked to Increased Risk of Heart Attack 15747 1HIV Drugs Linked to Increased Risk of Heart Attack 15747 2HIV Drugs Linked to Increased Risk of Heart Attack 15747 3Sonic Innovations Celebrates 10 Year Anniversary 15745 1Sonic Innovations Celebrates 10 Year Anniversary 15745 2Sonic Innovations Celebrates 10 Year Anniversary 15745 3Genoptix Announces 2008 Annual Stockholders Meeting and Date of Record 15743 1AMERIGROUP Successful Bidder in DC RFP 15741 1AMERIGROUP Successful Bidder in DC RFP 15741 2
(Date:8/21/2008)... New names and fresh websit... UME/GME administration software , ... one45 Software, a leading provider of healthcare ... of Cytiva Software Inc. (CRX:TSX.V), announced to...hcare education administration products., , ,Compl...
(Date:8/20/2008)... NEWTON, Mass., Aug. 20 /PRNewswire/ -- Questex M...o-business media company and owner of,American Spa... and the,International Beauty Shows, the Internati...) and the SPATEC appointment events today announce...stry portals SpaTrade (, http://www.SpaTrade.com ...
(Date:8/20/2008)... Survey Report Is Available at http://ww...Newswire/ -- A new survey released today,documents...re leveraging,health information technology (HIT) ...The survey results highlight the need for many HIT...dization and,interoperability to optimize clinical...
(Date:8/20/2008)...use postponed reproductive onset in teen, adult fe...EDNESDAY, Aug. 20 (HealthDay News) -- Alcoholism i...ccording to a study that compared women,s and men,... age when they had their first child. , The re...ian twins born between 1893-1964 (3,634 female and...
Breaking Medicine News(10 mins):Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 2Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 3Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 4Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 2Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 3Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 2Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 3Health News:Women's Alcohol Use Tied to Delayed Childbearing 2
...hould have enough Calcium in their diet, or may ri...a recent study. // The study was conducted in rat ...s from Tohoku University in Japan to find out whet...ss, the bone surrounding the roots of teeth. They ...
... (EBM) is acclaimed as the "gold-standard" amongst...nd, EBM has shown //support and on the other, has ...ractices, during the least interaction phase with ...tices. Majority of CAM practices are difficult, an...
... cause of end-stage kidney disease worldwide, an i...ents or a kidney transplant for survival. // A res...al Center and the University of Heidelberg has pro...h diabetes from developing severe kidney failure o...
...k are facing one of the worst gastroenteritis epid...f gear, with patients coming// in droves for relie...stomach cramps, which can continue for a few days ...ealth-care centers offering facilities in the grea...
Other Medicine News:Health News:Breastfeeding Mothers Need Calcium to Guard Against Periodontal Diseases 2Health News:Is Evidence-based Medicine Enough to Support Additional Research in Alternative Medicine? 2Health News:A Gene Associated With Severe Kidney Failure in Diabetes Found 2
3D Cranial is the most widely used surgical navigation software. Navigate with confidence and ease with displayed Zone of Accuracy and several fully automated features. 3D Cranial offers seamless int
The D185 is the only stimulator with FDA clearance for this application. The D185 allows transcranial motor evoked potentials to be used in surgical procedures such as scoliosis correction, spinal tu
Designed for the effective positioning of patients during spinal surgery, the frame gives the surgeon a remarkably simple and versatile surgical tool.
The Wilson Plus Radiolucent Wilson Frame delivers unrestricted radiolucency and C-arm integration with a convenient and stable method of maintaining patients in a flexed position for laminectomy, dec
Medicine Products: